Aerial transmission of SARS-CoV-2 virus (and pathogens in general) through environmental e-cigarette aerosol - Sussman, Roberto A; Golberstein, Eliana; Polosa, Riccardo (medRxiv, 2021)
We examine the plausibility, scope and risks of aerial transmission of pathogens (including the SARS-CoV-2 virus) through respiratory droplets carried by exhaled e–cigarette aerosol (ECA). Observational and laboratory data suggests considering cigarette smoking and mouth breathing through a mouthpiece as convenient proxies to infer the respiratory mechanics and droplets sizes and their rate of emission that should result from vaping. To quantify direct exposure distance we model exhaled ECA flow as an intermittent turbulent jet evolving into an unstable puff, estimating for low intensity vaping (practiced by 80-90 % of vapers) the emission of 6-200 (mean 79.82, standard deviation 74.66) respiratory submicron droplets per puff a horizontal distance spread of 1-2 meters, with intense vaping possibly emitting up to 1000 droplets per puff in the submicron range a distance spread over 2 meters. Since exhaled ECA acts effectively as a visual tracer of its expiratory flow (because of its dynamical and optical properties) bystanders become instinctively aware that possible direct contagion might occur only in the direction and scope of the jet. In a home or restaurant scenarios without face mask wearing bystanders exposed to ECA expirations by an infectious vaper face a 1 % increase of risk of contagion with respect to a “control case” scenario defined by exclusively rest breathing without vaping. This relative added risk becomes 5 − 17 % for high intensity vaping, 44 − 176 % and over 260 % for speaking for various periods or coughing (all without vaping). Face masks of common usage effectively protect wearers from respiratory droplets possibly emitted by mask-less vapers as long as they avoid direct exposure to the visible exhaled vaping jet. We estimate that disinfectant properties of glycols in ECA are unlikely to act efficiently on pathogens carried by vaping expirations under realistic conditions.Competing Interest StatementRAS has no competing interests to declare. EG is currently employed by Myriad Pharmaceuticals, an independent company that manufactures e−liquids and vaping devices in New Zealand. She also provides consultancy work on research and development, regulatory affairs support, and formulation to several independent vaping companies in the Paci c Region. In the past she has worked for several pharmaceutical companies, including GlaxoSmithKline and Genomma Lab. She is also a member of the standards committee of the VTANZ and UKVIA. RP is full time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Novartis, Duska Therapeutics, Alfa-Wassermann, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects. RP is also currently involved in the following pro bono activities, scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4).Clinical TrialN/AFunding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, RAS, upon reasonable request.